Diabetes patients and advocacy organizations are urging the drug side of FDA to catch up to its device counterpart and look beyond hemoglobin A1c as an endpoint for diabetes products.
Diabetes advocates are also asking FDA to relax requirements for cardiovascular outcomes studies of diabetes drugs pre-approval and for the agency to develop a guidance that outlines a